Branded Generic and Proprietary Medicinal Products - Group 10
A Contract Award Notice
by BUSINESS SERVICES ORGANISATION, PROCUREMENT AND LOGISTICS SERVICE
- Source
- OJEU
- Type
- Contract (Supply)
- Duration
- 5 year (est.)
- Value
- £10M
- Sector
- HEALTH
- Published
- 30 Sep 2022
- Delivery
- To 14 Dec 2030 (est.)
- Deadline
- n/a
Concepts
Location
Belfast
2 buyers
32 suppliers
- Aspire Pharma Hampshire
- B Braun Sheffield
- Baxter Healthcare Norfolk
- Bayer Berkshire
- Bowmed Ibisqus Wrexham
- Bristol Myers Squibb Pharmaceuticals Middlesex
- DR Reddys Laboratories Yorkshire
- Focus Pharmaceuticals London
- Glaxosmithkline London
- Glenmark Pharmaceuticals Europe Middlesex
- Grunenthal Stockenchurch
- Janssen Cilag Buckinghamshire
- Kent Pharma Kent
- Kyowa Kirin Galashiels
- Macure Pharma London
- Martindale Pharma Essex
- Merck Sharp & Dohme London
- Mercury Pharmaceuticals London
- Morningside Pharmaceuticals Loughborough
- Neon Healthcare Hertfordshire
- Norgine Pharmaceuticals Middlesex
- Pfizer Kent
- Rosemont Pharmaceuticals Leeds
- Sandoz Surrey
- Sun Pharma Uxbridge
- Teva Castleford
- Thornton & Ross Huddersfield
- Tillomed Laboratories Luton
- Typharm Norfolk
- Viatris Healthcare Potters Bar
- Wockhardt Wrexham
- Zentiva London
Description
Branded Generic and Proprietary Medicinal Products - Group 10
Total Quantity or Scope
Branded Generic and Proprietary Medicinal Products - Group 10 [3970432] is established under the Medicinal Products Dynamic Purchasing System [131864]. The contract is awarded on behalf of the following contract participants: (i) Belfast Health and Social Care Trust (BHSCT); (ii) South Eastern Health and Social Care Trust (SEHSCT); (iii) Northern Health and Social Care Trust (NHSCT); (iv) Southern Health and Social Care Trust (SHSCT); (v) Western Health and Social Care Trust (WHSCT); (vi) Northern Ireland Ambulance Service (NIAS); (vii) Northern Ireland Blood Transfusion Service (NIBTS); (viii) Business Services Organisation (BSO); (ix) Public Health Agency (PHA); (x) Department of Health, Northern Ireland (DoH(NI)); (xi) Health and Social Care Board (HSCB) (now Strategic Planning and Performance Group).
Award Detail
1 | Aspire Pharma (Hampshire)
|
2 | B Braun (Sheffield)
|
3 | Baxter Healthcare (Norfolk)
|
4 | Bayer (Berkshire)
|
5 | Bowmed Ibisqus (Wrexham)
|
6 | Bristol Myers Squibb Pharmaceuticals (Middlesex)
|
7 | DR Reddys Laboratories (Yorkshire)
|
8 | Focus Pharmaceuticals (London)
|
9 | Glaxosmithkline (London)
|
10 | Glenmark Pharmaceuticals Europe (Middlesex)
|
11 | Grunenthal (Stockenchurch)
|
12 | Janssen Cilag (Buckinghamshire)
|
13 | Kent Pharma (Kent)
|
14 | Kyowa Kirin (Galashiels)
|
15 | Macure Pharma (London)
|
16 | Martindale Pharma (Essex)
|
17 | Merck Sharp & Dohme (London)
|
18 | Mercury Pharmaceuticals (London)
|
19 | Morningside Pharmaceuticals (Loughborough)
|
20 | Neon Healthcare (Hertfordshire)
|
21 | Norgine Pharmaceuticals (Middlesex)
|
22 | Pfizer (Kent)
|
23 | Rosemont Pharmaceuticals (Leeds)
|
24 | Sandoz (Surrey)
|
25 | Sun Pharma (Uxbridge)
|
26 | Teva (Castleford)
|
27 | Thornton & Ross (Huddersfield)
|
28 | Tillomed Laboratories (Luton)
|
29 | Typharm (Norfolk)
|
30 | Viatris Healthcare (Potters Bar)
|
31 | Wockhardt (Wrexham)
|
32 | Zentiva (London)
|
Award Criteria
Compliance with Contract Scope and Specification | _ |
Supply and Delivery of Product: Same Working Day Delivery | 5.0 |
Supply and Delivery of Product: Wholesale Distribution | 5.0 |
Continuity of Supply: Minimum Committed Stockholding | 8.0 |
Governance, Quality Control and Risk: Pharmaceutical Quality Assessment (PQA) Section 1 | _ |
Governance, Quality Control and Risk: Pharmaceutical Quality Assessment (PQA) Sections 2 - 6 (inclusive) | 40.0 |
PRICE | 42.0 |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Award on basis of price and quality.
Other Information
The estimated total value of contract (excluding VAT) is GBP 9 000 000 to GBP 43 000 000. This maximum value in the range takes into consideration and accounts for all available extension provision as outlined in the SS17bc Commercial Conditions of Contract for Supplies Contracts document and provides for potential growth of up to 50% over the course of the contract. The total value of contract (detailed in section V.2.4) awarded to each of the Contractors indicated in this notice is based on an initial contract period of 24 months. It is important to note that there is available provision to extend this initial contract period in accordance with Section 2 of the SS17bc Commercial Conditions of Contract for Supplies Contracts document.
Reference
- OJEU 536845-2022